Literature DB >> 24368848

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo.

Kishore V Kuchibhotla1, Susanne Wegmann, Katherine J Kopeikina, Jonathan Hawkes, Nikita Rudinskiy, Mark L Andermann, Tara L Spires-Jones, Brian J Bacskai, Bradley T Hyman.   

Abstract

Alzheimer's disease (AD) is pathologically characterized by the deposition of extracellular amyloid-β plaques and intracellular aggregation of tau protein in neurofibrillary tangles (NFTs) (1, 2). Progression of NFT pathology is closely correlated with both increased neurodegeneration and cognitive decline in AD (3) and other tauopathies, such as frontotemporal dementia (4, 5). The assumption that mislocalization of tau into the somatodendritic compartment (6) and accumulation of fibrillar aggregates in NFTs mediates neurodegeneration underlies most current therapeutic strategies aimed at preventing NFT formation or disrupting existing NFTs (7, 8). Although several disease-associated mutations cause both aggregation of tau and neurodegeneration, whether NFTs per se contribute to neuronal and network dysfunction in vivo is unknown (9). Here we used awake in vivo two-photon calcium imaging to monitor neuronal function in adult rTg4510 mice that overexpress a human mutant form of tau (P301L) and develop cortical NFTs by the age of 7-8 mo (10). Unexpectedly, NFT-bearing neurons in the visual cortex appeared to be completely functionally intact, to be capable of integrating dendritic inputs and effectively encoding orientation and direction selectivity, and to have a stable baseline resting calcium level. These results suggest a reevaluation of the common assumption that insoluble tau aggregates are sufficient to disrupt neuronal function.

Entities:  

Keywords:  neuronal networks; paired helical filaments; tau pathology

Mesh:

Substances:

Year:  2013        PMID: 24368848      PMCID: PMC3890777          DOI: 10.1073/pnas.1318807111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration.

Authors:  Xiaoyu Li; Yatender Kumar; Hans Zempel; Eva-Maria Mandelkow; Jacek Biernat; Eckhard Mandelkow
Journal:  EMBO J       Date:  2011-10-18       Impact factor: 11.598

2.  Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Authors:  Zdenek Berger; Hanno Roder; Amanda Hanna; Aaron Carlson; Vijayaraghavan Rangachari; Mei Yue; Zbigniew Wszolek; Karen Ashe; Joshua Knight; Dennis Dickson; Cathy Andorfer; Terrone L Rosenberry; Jada Lewis; Mike Hutton; Christopher Janus
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

Review 3.  Development of tau aggregation inhibitors for Alzheimer's disease.

Authors:  Bruno Bulic; Marcus Pickhardt; Boris Schmidt; Eva-Maria Mandelkow; Herbert Waldmann; Eckhard Mandelkow
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

4.  Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.

Authors:  A B Rocher; J L Crimins; J M Amatrudo; M S Kinson; M A Todd-Brown; J Lewis; J I Luebke
Journal:  Exp Neurol       Date:  2009-08-07       Impact factor: 5.330

5.  Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.

Authors:  Leora M Fox; Christopher M William; David H Adamowicz; Rose Pitstick; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

6.  Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks.

Authors:  Kishore V Kuchibhotla; Samuel T Goldman; Carli R Lattarulo; Hai-Yan Wu; Bradley T Hyman; Brian J Bacskai
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

7.  Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease.

Authors:  Christine Grienberger; Nathalie L Rochefort; Helmuth Adelsberger; Horst A Henning; Daniel N Hill; Julia Reichwald; Matthias Staufenbiel; Arthur Konnerth
Journal:  Nat Commun       Date:  2012-04-10       Impact factor: 14.919

8.  Differential connectivity and response dynamics of excitatory and inhibitory neurons in visual cortex.

Authors:  Sonja B Hofer; Ho Ko; Bruno Pichler; Joshua Vogelstein; Hana Ros; Hongkui Zeng; Ed Lein; Nicholas A Lesica; Thomas D Mrsic-Flogel
Journal:  Nat Neurosci       Date:  2011-07-17       Impact factor: 24.884

9.  In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.

Authors:  Pablo D Perez; Gabrielle Hall; Tetsuya Kimura; Yan Ren; Rachel M Bailey; Jada Lewis; Marcelo Febo; Naruhiko Sahara
Journal:  Mol Neurodegener       Date:  2013-02-04       Impact factor: 14.195

10.  Are tau aggregates toxic or protective in tauopathies?

Authors:  Catherine M Cowan; Amrit Mudher
Journal:  Front Neurol       Date:  2013-08-13       Impact factor: 4.003

View more
  81 in total

1.  Ectopic Expression Induces Abnormal Somatodendritic Distribution of Tau in the Mouse Brain.

Authors:  Atsuko Kubo; Shouyou Ueda; Ayaka Yamane; Satoko Wada-Kakuda; Mai Narita; Makoto Matsuyama; Akane Nomori; Akihiko Takashima; Taisuke Kato; Osamu Onodera; Motohito Goto; Mamoru Ito; Takami Tomiyama; Hiroshi Mori; Shigeo Murayama; Yasuo Ihara; Hiroaki Misonou; Tomohiro Miyasaka
Journal:  J Neurosci       Date:  2019-06-24       Impact factor: 6.167

Review 2.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 3.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

4.  Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.

Authors:  Michiyo Iba; Jennifer D McBride; Jing L Guo; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2015-07-07       Impact factor: 17.088

5.  Tau13 Antibody Preferentially Immunoprecipitates High Molecular Weight Tau Proteins.

Authors:  Andrew Umstead; Irving E Vega
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

6.  Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach.

Authors:  Sarah N Fontaine; Alexandria Ingram; Ryan A Cloyd; Shelby E Meier; Emily Miller; Danielle Lyons; Grant K Nation; Elizabeth Mechas; Blaine Weiss; Chiara Lanzillotta; Fabio Di Domenico; Frederick Schmitt; David K Powell; Moriel Vandsburger; Jose F Abisambra
Journal:  Neurobiol Aging       Date:  2017-04-18       Impact factor: 4.673

7.  In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.

Authors:  Jorge Sepulcre; Aaron P Schultz; Mert Sabuncu; Teresa Gomez-Isla; Jasmeer Chhatwal; Alex Becker; Reisa Sperling; Keith A Johnson
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

Review 8.  Calcium's role as nuanced modulator of cellular physiology in the brain.

Authors:  Hilaree N Frazier; Shaniya Maimaiti; Katie L Anderson; Lawrence D Brewer; John C Gant; Nada M Porter; Olivier Thibault
Journal:  Biochem Biophys Res Commun       Date:  2016-08-20       Impact factor: 3.575

Review 9.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

10.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.